Hospital Inpatient Pipeline Therapies Report

IPD Analytics' Hospital Inpatient Pipeline Therapies Report for 2024 focuses on potential approvals and launches that will impact hospitals and health-systems in the near term.

This report offers hospital pharmacy leaders visibility into potential FDA approvals for budget planning purposes for the current fiscal year. The delineation of pipeline therapies into hospital inpatient, professionally administered, and self-administered specialty categories enables pharmacy leaders to stratify the potential costs and revenue from new product launches by type of service.

Based on the late-stage pipeline, the number of hospital inpatient therapies nearing potential FDA approval is expected to continue to increase; these pipeline therapies include antimicrobials, which are often high-cost products. The report examines these products and many others used for inpatient therapy.